Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...
Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...
− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, ...
The global CRO market is projected to hit almost $63 billion by the end of the decade, growing an average of 7.39% annually from 2025 to 2030, according to a new report from Irish-based market ...
New data show that applying AI to the migration of translated COAs into eCOA platforms can meaningfully reduce errors, accelerate localization workflows, and support broader global patient ...
Celiac disease represents a growing global health concern, with current management limited to lifelong adherence to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback